We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+32.82%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.14B
AUM Growth
+$551M
Cap. Flow
+$421M
Cap. Flow %
37.05%
Top 10 Hldgs %
39.86%
Holding
141
New
51
Increased
36
Reduced
11
Closed
41

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$18.2M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$10.6M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$10.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.48M
5
SRACU
Stable Road Acquisition Corp. Unit
SRACU
+$4.41M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$9.51M
3
SNN icon
Smith & Nephew
SNN
+$8.66M
4
BAX icon
Baxter International
BAX
+$4.96M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 26.48%
2 Industrials 0.92%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGC
51
PUT
Canopy Growth
CGC
$419M
$6.33M 0.56%
30,000
+2,500
+9% +$496K
AUPH icon
52
Aurinia Pharmaceuticals
AUPH
$2.05B
$5.41M 0.48%
+267,050
New +$2.46M
CNMD icon
53
CONMED
CNMD
$1.5B
$5.18M 0.46%
46,330
-1,170
-2% -$125K
GH icon
54
CALL
Guardant Health
GH
$22.2B
$5.16M 0.45%
+66,000
New +$4.76M
MJ icon
55
CALL
Amplify Alternative Harvest ETF
MJ
$108M
$5.14M 0.45%
+25,000
New +$5.51M
APYX icon
56
Apyx Medical
APYX
$129M
$4.85M 0.43%
573,782
+147,910
+35% +$1.07M
GH icon
57
Guardant Health
GH
$22.2B
$4.68M 0.41%
+59,960
New +$4.32M
EXAS
58
PUT
DELISTED
Exact Sciences
EXAS
$4.62M 0.41%
+50,000
New +$4.4M
IMMU
59
PUT
DELISTED
Immunomedics Inc
IMMU
$4.61M 0.41%
+218,000
New +$3.85M
AXNX
60
DELISTED
Axonics, Inc. Common Stock
AXNX
$4.53M 0.4%
+163,490
New +$3.9M
CI icon
61
PUT
Cigna
CI
$72B
$4.5M 0.4%
+22,000
New +$4.03M
SRACU
62
DELISTED
Stable Road Acquisition Corp. Unit
SRACU
$4.49M 0.39%
+435,850
New +$4.41M
MMSI icon
63
CALL
Merit Medical Systems
MMSI
$5.48B
$4.43M 0.39%
+142,000
New +$4.07M
OTIC
64
DELISTED
Otonomy, Inc.
OTIC
$4.37M 0.38%
1,140,163
+146,700
+15% +$358K
QGEN icon
65
Qiagen
QGEN
$8.88B
$4.22M 0.37%
+117,674
New +$4.37M
BYND icon
66
PUT
Beyond Meat
BYND
$214M
$4.08M 0.36%
54,000
+36,500
+209% +$3.39M
IMVTU
67
DELISTED
Immunovant, Inc. Units
IMVTU
$4.05M 0.36%
+165,170
New +$3.56M
HZNP
68
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.95M 0.35%
+109,000
New +$3.34M
MASI
69
DELISTED
Masimo
MASI
$3.86M 0.34%
24,409
+4,310
+21% +$648K
LAB icon
70
Standard BioTools
LAB
$315M
$3.8M 0.33%
1,090,830
+590,830
+118% +$2.08M
HCA icon
71
PUT
HCA Healthcare
HCA
$89.2B
$3.25M 0.29%
+22,000
New +$2.95M
MNTA
72
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.23M 0.28%
+163,490
New +$2.61M
TGTX icon
73
TG Therapeutics
TGTX
$7.65B
$3.08M 0.27%
277,639
-77,080
-22% -$586K
IOVA icon
74
CALL
Iovance Biotherapeutics
IOVA
$2.89B
$3.02M 0.27%
+109,000
New +$2.48M
NTRA icon
75
Natera
NTRA
$45.5B
$2.57M 0.23%
76,300
+46,300
+154% +$1.71M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Pura Vida Investments held 141 positions worth $1.14B, up 94% from $585M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Pura Vida Investments deployed $421M of net new capital in Q4 2019, opening 51 new positions and adding to 36 existing holdings. Its largest new stake was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 40% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Establishment Labs, an estimated $1.39M trimmed.

  • Pura Vida Investments's largest Q4 2019 buy was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2019, an estimated $18.2M increase.
  • Pura Vida Investments's biggest Q4 2019 reduction was Establishment Labs, cutting an estimated $1.39M.
  • Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q4 2019, selling an estimated $11.1M.
  • Pura Vida Investments's ten largest holdings make up 40% of its $1.14B portfolio in Q4 2019.
  • Pura Vida Investments opened 51 new positions and closed 41 in Q4 2019.
  • Pura Vida Investments's portfolio value rose 94% quarter-over-quarter to $1.14B.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.